Lincoln International: Biosector, a subsidiary of Brenntag, has been sold to Croda
Lincoln International is pleased to announce that it advised Brenntag AG in the sale of Biosector A/S to British specialty chemicals company Croda International plc for a total consideration of Euro 72 million.
Biosector, headquartered in Frederikssund, Denmark, is a world leading adjuvant specialist for vaccines serving the top key human and veterinary vaccine producers, innovative R&D organizations and blood fractioning companies. The product portfolio comprises well-known and innovative aluminium-based and saponin-based adjuvants renowned as Alhydrogel®, Adju-Phos® and Quil-A®. Biosector is running the only aseptic and GMP certified manufacturing site in the world and comprises industry leading R&D know-how resulting in a promising pipeline of innovative next generation adjuvants.
Croda International plc (“Croda”), established in 1925, is the name behind high performance ingredients and technologies in some of the world’s biggest and most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere. Croda has over 4,300 employees, working together as one global team across manufacturing sites and offices in 37 countries. Croda is a FTSE100 company with a flexible structure that allows it to focus on developing and delivering innovative, sustainable ingredients that its customers can build on in: Personal Care, Life Sciences, Performance Technologies and Industrial Chemicals.
Anthony Gerace, Brenntag Group’s Managing Director Mergers & Acquisitions: “We believe it is the right time to hand over Biosector to a company that is well positioned and focused on the health care sector. We are confident that Croda will further develop the business and take it to the next level globally.”
Lincoln International acted as the exclusive financial advisor to the seller, managing a competitive M&A process with strong interest from multiple international strategic as well as financial investors.